DOCSLIB.ORG

Referenees 323

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Referenees 323 Referenees 323 Referenees 1. ABAZA, A., RUTLISBERGER, P.A.: presse med. 68, 963 (1960). 2. ABEOO, G., DZEDIN, T., LUNDHOLM, L., OLSSON, L., SVEDlIIYR, N.: Life Sci. 8, 353 (1969). 3. ABLAD, B., BROGARD, M., Ek, L.: Acta. Pharmaool.Toxicol. 25, Suppl. 2, 9 (1967). 4. - JOHNSSON, G., NORRBY, A., SÖLVELL, L.: Acta Pharmaool. Toxicol. 25, Suppl. 2, 85 (1967). 5. ABRAHAlIISEN, A.M., KIIL, F.: Brit. med. J. 1,456 (1966). 6. ABRAlIIS, W.B., BECKER, M.C., LEWIS, D.W., Kn.LOUGH, J.H.:Amer. J. Cardiol. 5, 634 (1960). 7. - LEWIS, D. W., SHOSHKES, M., ROTHl!'ELD, E., BECKER, M.: Amine oxidase inhibitors in angina pectoris. Symposium International on "The Catecholamines in Cardiovascular Pathology". Burlington (Vermont), 23 Aug. 1959, Summary, p. 6. 8. ACETO, M.D., KINNARD, W.J., BUCKLEY, J.P.: Fed. Proc. 20, 102 (1961). 9. --- Fed. Proc. 22, 304 (1962). 10. AELLIG, W.H., PRICHARD, B.N.C., RICHARDSON, G.A.: Brit. J. Pharmacol. 37, 527 (1969). 11. AFONSO, S.: Amer. J. Physiol. 216, 297 (1969). 12. - O'BRIEN, G.S.: Circulat. Res. 20,403 (1967). 13.- - CRUlIIPTON, C.W.: a) J. Lab. clin. Med. 68, 852 (1966). b) Circulat. Ras. 22,43 (1968). 14. AHLQUIST, R.P.: Amer. J. Physiol. 153,586 (1948). 15. - Ann. Rev. Pharmacol. 8, 259 (1968). 16. - HUGGINs, R.A., WOODBURY, R.A.: J. Pharmacol. exp. Ther. 89,271 (1947). 17. AKKER, S. van den, BlJLslIIA, U.G., VAN DONGEN, K., TEN TmJE, J.H.: Arzneimittel- Forsch. 7, 15 (1957). 18. ALBERT, A.: J. Lancet 81, 112 (1961). 19. ALnINGER, E. E.: Circulat. Res. 22, 589 (1968). 20. ALGAN, 0., KIENLE, H.: Med. Mschr. 21, 232 (1967). 21. ALLANBY, K.D., Cox, A.G.C., MACLEAN, K.S., PRICE, T.M.L., SOUTHWELL, N.: Lancet 1961 1,138. 22. ALLlIIARK, M.G., Lu, F.C., CARlIIICHAEL, E., LAVALLEE, A.: Amet. Rev. Tuberc. 68, 199 (1953). 23. ALTlIIAN, G.E., RISElIIAN, J.E.F., KORETSKY,S.: Amer. J. med. Sei. 240, 66 (1960). 24. ALTSCHULE, M.D.: Amer. Haart J. 27, 322 (1944). 25. ALVARO, A.B., MAcALPIN, R.N., KATTUs, A.A.: Circulation 36, Suppl. 2, 51 (1967). 26. AlIIMERlIIANN, E.O.: Med. Welt 18, 1498 (1967). 27. AlIISTERDAM, E.A., GORLIN, R., WOLFSON, S.: J. Amer. med. Aas. 210, 103 (1969). 28. - WOLFSON, S., GORLIN, R.: Ann' intern. Med. 68, 1151 (1968). 29. --- Amer. J. Cardiol. 23, 104 (1969). 30. --- Amer. J. Cardiol. 24, 305 (1969). 31. ANDERSON, F.F., CAMERON, A.: J. Amer. pharm. Aas. 39, 183 (1950). 32. - CRAVER, B.N.: J. Pharmaool. exp. Ther. 93,135 (1948). 33. ANDRUS, C.E.: Circulation 22, 979 (1960). 34. ANGARSKAYA, M.A., KHAnZHAI, Y.!., KOLESNIKOV,D.G., PROKOPENKO, A.P., Du­ BINSKY, A.A., SHUBOV, M.!.: KIin. Med. 36, 29 (1958), abstract in Circulation 18, 466 (1958). 35. ANGKAPINDu, A., STAFFORD, A., THORP, R.H.: Arch. int. Pharmacodyn. lI9, 194 (1959). 36. ANREP, G. V.: Medical Sciences 3, 245 (1936). 37 . ....;,. BARSOUM, G.S., KENAWY, M.R.: Gaz. Faculty Med. Cairo 2,1 (1947). 38. --- J. Pharm. Pharmaool. 1, 164 (1949). 39. --- MIsRAHY, G.: Brit. HeartJ: 8, 171 (1946). 40:....;,. -'- - ~Lancet 19471, 557. 41. -- SCHÖNBERG, A.: J. Pharm. Pharmacol. 5, 166 (1953). 42. -- TALAAT, M.: J. Physiol. (Lond.) 86, 431 (1936). 43. - BLALOCK, A., HAlIIlIIOUDA, M.: J. Physiol. (Lond.) 67, 87 (1929). 44. - HÄUSLER, H.: J. Physiol. (Lond.) 65, 357 (1928). 45. - KENAWY, M.R., BARSOUM, G.S.: Amer. Heart J. 37, 531 (1949). 46. ANTHONY, J.R., JICK, H., SPODICK, D.H.: Amer. Heart J. 77, 598 (1969). 47. ANTONIO, A., RoCHA E SILVA, M.: Circulat. Res. lI, 910 (1962). 48. APTHORP, G.H., CHAMBERLAIN, D.A., HAYWARD, G. W.: Brit. Heart J. 26, 218 (1964). 49. Aptin: Leaflet ASTRA (Sweden), p. 24 and 28. 50. ARAVANIS, C., LUlSADA, A.A.: Ann. intern. Med. 44, 1111 (1956). 324 Referenoes 51. ABBORELIUs, M., LEOEROF, H., MALM, A., MALlIIBORG, R. 0.: Brit. Heart J. 30, 407 (1968). 52. ABESKOG, N.H., ADOLFSsON, L.: Brit. med. J. 198911,601. 53• .ARlIIANn, P., PABCHT, A., LIOHAH, E., BRElIIOND, 0.: Gaz. Hõp. (Paris) 142, 205 (1970). 54. ARlIIBRUST, O.A., LEVINE, S.A.: Amer. J. med. Sci. 220, 127 (1950). 55. AmrnTAGE, A.K., BOSWOOD, J., LARGE, B.J.: Brit. J. Pharmacol. 18,59 (1961). 56. ARoNow, W.S., KAFLAN, M.A.: 0.) New EngI. J. Med. 280, 847 (1969); b) Ann. intem. Med. 70, 1072 (1969). 57. AsCHENDEOK, G.: Dtsch. med. J. 18, 137 (1965). 58. AsKANAZY, S.: Dtsch. Arch. kIin. Med. 58, 209 (1895). 59. AsTROM, H.: Brit. Hea.rt J. 30, 44 (1968). 60. ATTERHÖG, J.H., PORJE, G.: Svenska Lä.k.·Tidn. 83, 2071 (1966). 61. AUDIER, M., SERRADIl\IIGNI, A., POGGI, L., BORY, M., DIANE, P.: Arch. Meeliterr. med. 5, 265 (1969). 62. - ARNOUX, E., GmAUD, M.: Sem. Hõp. (TMrapeutique) 42, 355 (1966). 63. - DEVIN, R., BONNEAU, H., RUF, G.: Presse med. 62, 803 (1954). 64. AYAD, H.: Lancet 19491, 305. 65. BABEL, J., STANGOS, N.: Arch. Ophtha.1. 30, 197 (1970). 66. BAOHAND, R. T., SOlllANI, P., HARDlIIAN, H. T.: Olin. Res. 18, 221 (1968). 67. BAOQ, Z.M., CmrrlIIOL, J., DALLElIIAGNE, M.J., HAZARD, R., LABARRE, J., REusE, J.J., WELSCH, M.: Pharma.codynamie biochimique, Ed. Sciences et Lettres, Liege, 1961, p. 176. 68. BAEDER, D.H.: Fed. Proc. 20, 103 (1961). 69. BAER, S., HEINE, W.I., GELFOND, D.B.: Amer. J. med. Sci. 215, 542 (1948). 70. BAGOURI, M.M.: J. Pharm. Pharmacol. 1, 177 (1949). 71. BAISSE, J.: Bull. Soe. chim. Fr. p. 769 (1949). 72. BAKER, J.B.E.: J. PhysioI. (Lond.) 115, 30P (1951). 73. BAKER, L.D., LESBIN, S.J., SHARlIIA, G.V.R.K., MEssER, J.V.: Amer. J. CardioI. 23, 104 (1969). 74. - MATHUR, V.S., LESBIN, S.J.,MESSER, J. V.: Oircula.tion 38, SuppI. 6, 37 (1968). 75. BAKST, H., KlsSIN, M., LEmoWITz, S., RINZLER, S.: Amer. Heart J. 38, 527 (1948). 76. BALAGUER-VINTRO, I., OTER RODRIGUEZ, R., DUARTE MANTILLA, G., VILA.LTA BERNET, 0.: An. Med. (Med.) 55, 97 (1969). 77. BALATRE, P., MERLEN, J.F.: TMtapie 15, 83 (1960). 78. -- GRANJEAN, L.: Presse med. 57, 1067 (1949). 79. BALCON, R.,JEWITT, D.E., DAVIES,J.P.H., ORAlll, S.: 0.) Amer. HeartJ. 74, 582 (1967); b) Lancet 1988II, 917. 80. - MALeY, W.O., SOWTON, E.: Brit. med. J. 3, 91 (1968). 81. BALDES, E.J., HERRIOK, J.F.: Proc. Soe. exp. BioI. (N.Y.) 37,432 (1937). 82. BALL, K.P.: Lancet 19481,116. 83. BANES, D.: J. pharm. Sci. 57, 893 (1968). 84. BANKS, T., SHUGOLL, G.I.: J. Amer. med. Ass. 200, 1031 (1967). 85. BANSE, H.J., ZAHNOW, W.: Münch. med. Wschr. 52, 2036 (1958). 86. BARBARESl, F., BACUZZI, E., MANFREDI, M., STARCICH, R.: G. Olin. med. 47, 849 (1966). 87. BARBI, G.L., TALLONE, G.: Olin. ter. 32, 236 (1965). 88. BARGHEER, R., FIEGEL, G., SAITO, S., GUTTlIIANN, W.: Arzneimittel-Forsch. 17, 288 (1967). 89. BAROLDI, G., MANTERo, 0., SOOMOZONI, G.: Oircula.t. Rea. 4, 223 (1956). 90. BAROUSCH, R.: Wien. kIin. Wschr. 79, 856 (1967). 91. BARRERA, J.A., TURIELLA, R.G.: Pren. med. argent. 47, 111 (1959). 92. BARRETT, A.M.: J. Pharm. Pharma.coI. 21, 241 (1969). 93. - CROWTHER, A.F., DUNLOP, D., SHANKS, R.O., SlIIITH, L.H.: Arch. Pha.rma.coI. exp. Path. 259, 152 (1968). 94. BARRETT, O. T.: S. Arr. med. J. 28, 734 (1952). 95. BARRY, A.J., DALY, J. W., PRUETT, E.D.R., STEINlIIETZ, J.R., BIRKHEAD, N.O., RODAUL, K.: Amer. J. CardioI. 17, 1 (1966). 96. BARSOUlll, G.S., KENAWY, M.R.: Amer. Heart J. 47, 297 (1954). 97. BARTELSTONE, H.J., SCHERLAG, B.J., CRANEFlELD, P.F., HOFFlllAN, B.F.: Bull. N.Y. Acad. Med. 42, 951 (1966). 98. BARTHEL, W., MARKWARDT, F.: Biochem. Pharmacol. 18, 1899 (1969). 99. BARZIN, J.: Rev. med. Liege 23, 135 (1968). 100. - FRESON, A.: Brux.-mM. 49, 105 (1969). 101. BASTENIE, P.A., VANHAELST, L., NEVE, P.: Lancet 198711,1221. 102. BATElIIAN, F.J.A.: Lancet 1967II, 418. 103. BATLOUNI, M., BETOLAlllI, V., DUPRAT, R.: Arqui. Bruil. CardioI. 21, 321 (1968). Referenees 325 104. BATTERMAN, R.C.: J. Amer. med. Ase. 157, 1333 (1955). 105. - Ann. N.Y. Acad. Sci. 84, 499 (1856). 106. - GROSSMAN, A.J., SOHWIMMER, J., BUCKMAN, A.L.: J. Amer. med. Ase. 157,234 (1955). 107. - MOURAToFF, C.J.: Calif. Med. 98, 318 (1963). 108. BATTOCK, D.J., ALVAREZ, H., CHIDSEY, C.A.: Circulation 38, Suppl. 6, 39 (1968). 109. --- Circulation 39, 157 (1969). 110. BAUDINE, A., CHAILLET, F., CHARLnm, R., HOSSLET, A.: Arch. int. Pharmacodyn. 189, 469 (1967). 111. BAUE, A.: J. Amer. med. Ase. Z08, 849 (1969). 112. BAUMGARTEN, A.: Med. J. Aust. 49, 429 (1962). 113. BAY, G., LARSEN, L.P., LORENTSEN, E., SIVERTSSEN, E.: Brit. med. J. 19871, 141. 114. BAYLEY, R.H., LA DUE, J.S., YORK, D.J.: Amer. Heart J. Z7, 657 (1944). 115. BEAUMONT, J.L., COBLENTZ, B., MAURICE, P., CHEVALIER, H., LENEGRE, J.: Sem. Hap. Paris Z8, 1926 (1952). 116. BECK, C.S., LEIGRNINGER, D.S.: J. Amer. med. Aas. 158, 1226 (1954). 117. BECKER, A.: Medizinische 52, 2152 (1958). 118. BECKER, M.C.: J. Amer. med. Aas. 203, 56 (1968). 119. BECKMAN, H.: Pharmaoology in Clinical Practice, 1 vol., 839 pp. Philadelphia and Lon- don: Saunders and Co. 1954, p. 191. 120. BECKSCHÄFER, W.: Arzneimittel-Forsch. 18, 1079 (1968). 121. BEECHER, H.K.: J. Amer. med. Aas. 158,399 (1955). 122. - J. Amer. med. Aas. 159, 1602 (1955). 123. BEKAERT, J.: Personal communication 1968. 124. - AUBERT, P.: Ther. Umach. 18,317 (1961). 125. -- Ther. Umach.
Load more

Recommended publications
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Pharmaceutical Composition and Dosage Forms for Administration of Hydrophobic Drugs
    (19) & (11) EP 2 246 049 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.11.2010 Bulletin 2010/44 A61K 31/355 (2006.01) A61K 31/56 (2006.01) C07J 53/00 (2006.01) (21) Application number: 10173114.9 (22) Date of filing: 24.05.2004 (84) Designated Contracting States: • Fikstad, David T. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Salt Lake City, UT 84102 (US) HU IE IT LI LU MC NL PL PT RO SE SI SK TR • Zhang, Huiping Salt Lake City, UT 844121 (US) (30) Priority: 22.05.2003 US 444935 • Giliyar, Chandrashekar Salt Lake City, UT 84102 (US) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Walker, Ross Thomson 04753162.9 / 1 624 855 Potts, Kerr & Co. 15 Hamilton Square (71) Applicant: Lipocine, Inc. Birkenhead Salt Lake City, UT 84103 (US) Merseyside CH41 6BR (GB) (72) Inventors: Remarks: • Chen, Feng-Jing This application was filed on 17-08-2010 as a Salt Lake City, UT 84111 (US) divisional application to the application mentioned • Patel, Mahesh V. under INID code 62. Salt Lake City, UT 84124 (US) (54) Pharmaceutical composition and dosage forms for administration of hydrophobic drugs (57) Pharmaceutical compositions and dosage tion with improved dispersion of both the active agent forms for administration of hydrophobic drugs, particu- and the solubilizer. As a result of the improved dispersion, larly steroids, are provided. The pharmaceutical compo- the pharmaceutical composition has improved bioavail- sitions include a therapeutically effective amount of a hy- ability upon administration.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0215844 A1 Davis Et Al
    US 20090215844A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0215844 A1 Davis et al. (43) Pub. Date: Aug. 27, 2009 (54) COMPOSITIONS COMPRISING NEBVOLOL (60) Provisional application No. 60/577,423, filed on Jun. 4, 2004. (75) Inventors: Eric Davis, Morgantown, WV (US); John O'Donnell, Morgantown, WV (US); Peter Publication Classification Bottini, Morgantown, WV (US) (51) Int. Cl. A63L/353 (2006.01) Correspondence Address: A6II 3/40 (2006.01) FROST BROWN TODD, LLC A6II 3/4I (2006.01) 2200 PNCCENTER, 201 E. FIFTH STREET CINCINNATI, OH 45202 (US) (52) U.S. Cl. .......... 514/381: 514/456; 514/412: 514/423 (73) Assignee: Mylan Laboratories, Inc., Morgantown, WV (US) (57) ABSTRACT (21) Appl. No.: 12/366,866 Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart (22) Filed: Feb. 6, 2009 failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition Related U.S. Application Data comprising nebivolol and at least one other active agent, (62) Division of application No. 1 1/141,235, filed on May wherein the at least one other active agent is a cardiovascular 31, 2005. agent. Patent Application Publication Aug. 27, 2009 Sheet 1 of 4 US 2009/0215844 A1 Figure 1 50 Black Nebivolol (1.0 M) 500 white + tiebivoloi (1.0 (i)} s Black, Untreated S Swhite, untreated . 9 400 S 350. g 300 5 250 O 200 2. Untreated 1.0 Ramipriat Treatment (um) 'p < 0.05 and tip- 0.01 vs preincubation with nei olo alone (n =6) Patent Application Publication Aug.
    [Show full text]
  • Section B Changed Classes/Guidelines Final Version Date of Issue
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021 Section B Changed Classes/Guidelines Final Version Date of issue: 19th December 2020 1 A2B ANTIULCERANTS r2020 Combinations of specific antiulcerants with other substances, such as anti- infectives against Helicobacter pylori, antispasmodics, gastroprokinetics, that are for ulcers, gastro-oesophageal reflux disease or similar conditions are classified according to the antiulcerant substance. For example, proton pump inhibitors in combination with these anti-infectives are classified in A2B2. Combinations of antiulcerants with non-steroidal anti-inflammatories where the antiulcerant is present for gastric protection are classified in M1A1. A2B1 H2 antagonists R2002 Includes, for example, cimetidine, famotidine, nizatidine, ranitidine, roxatidine. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. A2B2 Proton pump inhibitors r2021 Includes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole. Combinations of proton pump inhibitors with gastroprokinetics for ulcers, gastro- oesophageal disease or similar conditions are classified here. Includes potassium- competitive acid blockers (P-CABs) such as revaprazan, tegoprazan, vonoprazan, etc. A2B3 Prostaglandin antiulcerants Includes misoprostol, enprostil. A2B4 Bismuth antiulcerants Includes combinations with antacids. A2B9 All other antiulcerants r2020 Includes all other products containing substances with antiulcerant action where the type of substance is not specified in classes A2B1 to
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • WO 2014/170786 Al 23 October 2014 (23.10.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/170786 Al 23 October 2014 (23.10.2014) P O P C T (51) International Patent Classification: 06419 (US). MAGUIRE, Bruce; 17 Waterhouse Lane, C07D 401/14 (2006.01) C07D 471/04 (2006.01) Chester, Connecticut 06412 (US). MCCLURE, Kim F.; C07D 413/14 (2006.01) C07D 487/04 (2006.01) 12 Willow Drive, Mystic, Connecticut 06355 (US). A61K 31/4725 (2006.01) A61P 7/00 (2006.01) PETERSEN, Donna N.; 107 Forsyth Road, Salem, Con A61K 31/519 (2006.01) necticut 06420 (US). PIOTROWSKI, David W.; 19 Beacon Hill Drive, Waterford, Connecticut 06385 (US). (21) International Application Number: PCT/IB20 14/060407 (74) Agent: OLSON, A. Dean; Pfizer Inc., Eastern Point Road MS8260-2141, Groton, CT 06340 (US). (22) International Filing Date: 3 April 2014 (03.04.2014) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 61/812,864 17 April 2013 (17.04.2013) US KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/880,336 20 September 2013 (20.09.2013) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/898,667 1 November 2013 (01.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]